Genes in panel
STRs in panel
Prev Next
Regions in panel
Prev Next

BabyScreen+ newborn screening

Gene: RFXANK

Green List (high evidence)

RFXANK (regulatory factor X associated ankyrin containing protein)
EnsemblGeneIds (GRCh38): ENSG00000064490
EnsemblGeneIds (GRCh37): ENSG00000064490
OMIM: 603200, Gene2Phenotype
RFXANK is in 6 panels

1 review

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Green List (high evidence)

Established gene-disease association.

Onset in infancy.

Treatment: BMT

Non-genetic confirmatory testing: flow cytometric analysis of HLA-DR expression on monocytes and B cells
Created: 14 Dec 2022, 7:26 a.m. | Last Modified: 14 Dec 2022, 7:26 a.m.
Panel Version: 0.1446

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
MHC class II deficiency, complementation group B MIM# 209920

Details

Mode of Inheritance
BIALLELIC, autosomal or pseudoautosomal
Sources
  • Expert Review Green
  • BeginNGS
Phenotypes
  • MHC class II deficiency, complementation group B , MIM#209920
Tags
treatable immunological
OMIM
603200
Clinvar variants
Variants in RFXANK
Penetrance
None
Panels with this gene

History Filter Activity

14 Dec 2022, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: rfxank has been classified as Green List (High Evidence).

14 Dec 2022, Gel status: 3

Added Tag, Added Tag

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Tag treatable tag was added to gene: RFXANK. Tag immunological tag was added to gene: RFXANK.

18 Sep 2022, Gel status: 3

Created, Added New Source, Set mode of inheritance, Set Phenotypes

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

gene: RFXANK was added gene: RFXANK was added to gNBS. Sources: BeginNGS,Expert Review Green Mode of inheritance for gene: RFXANK was set to BIALLELIC, autosomal or pseudoautosomal Phenotypes for gene: RFXANK were set to MHC class II deficiency, complementation group B , MIM#209920